ArticleNPJ precision oncology2026
SPOCK1 acts as a negative regulator of ferroptosis in non-small cell lung cancer.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related morbidity and mortality worldwide. Therefore, there is an urgent need to discover precise diagnostic markers and novel therapeutic strategies. A genome-wide association study (GWAS) was conducted using the Kunshan Elderly Cohort to identify genetic susceptibility factors underlying NSCLC. GWAS results identified that seven single-nucleotide polymorphisms (SNPs) were associated with NSCLC risk, including SPOCK1 (SPARC/osteonectin, CWCV, and Kazal-like domains proteoglycan (1), which emerged as a key candidate oncogene driving NSCLC progression. High expression of SPOCK1 in NSCLC tissues was associated with poor prognosis. Subsequently, using NSCLC cell lines with shRNA-mediated SPOCK1 knockdown (loss of function) and plasmid-mediated SPOCK1 overexpression (gain of function), we demonstrated that SPOCK1 significantly promotes in vitro NSCLC cell proliferation, migration, invasion, and cell cycle progression. Furthermore, in vivo mouse studies demonstrated that xenografted SPOCK1-knockdown NSCLC cells exhibited significantly reduced tumor growth and metastasis, whereas xenografted SPOCK1-overexpressing NSCLC cells enhanced tumor progression and metastasis. Mechanistically, SPOCK1 activates the JAK2/STAT3 signaling pathway by interacting with integrin alpha5 beta1 (α5β1) and subsequently upregulating SLC3A2 expression. This regulatory cascade promotes glutathione (GSH) biosynthesis and mitigates the accumulation of reactive oxygen species (ROS) and lipid peroxidation LPO), thereby suppressing ferroptosis in the NSCLC cells. Furthermore, Heat Shock Factor 1 (HSF1) is a critical upstream transcriptional regulator of SPOCK1. Notably, SPOCK1 acts as a pivotal mediator of the immunosuppressive microenvironment in the NSCLC tumors by inducing T-cell exhaustion and promoting infiltration of regulatory T cells (Tregs). In summary, SPOCK1 drives NSCLC progression by inhibiting ferroptosis and inducing an immunosuppressive microenvironment. Therefore, SPOCK1 may be a promising therapeutic target in NSCLC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.